WHO advises against remdesivir for Covid-19 treatment
WHO says there is 'no evidence based on currently available data that it does improve patient-important outcomes'.
US gives full approval for antiviral remdesivir to treat Covid-19
It can be administered to adults and children over the age of 12 who weigh more than 40kg who require hospitalisation, with emergency approval for its use on paediatric patients under the age of 12 weighing at least 3.5kg.
Remdesivir has ‘little or no effect’ on Covid-19 mortality, WHO study shows
Washington authorised the emergency use of the medicine on May 1, followed by a range of other countries and the European Union.